Quantifying synergy in the bioassay-guided fractionation of natural product extracts
Open Access
- 14 August 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (8) , e0235723
Abstract
Mixtures of drugs often have greater therapeutic value than any of their constituent drugs alone, and such combination therapies are widely used to treat diseases such as cancer, malaria, and viral infections. However, developing useful drug mixtures is challenging due to complex interactions between drugs. Natural substances can be fruitful sources of useful drug mixtures because secondary metabolites produced by living organisms do not often act in isolation in vivo. In order to facilitate the study of interactions within natural substances, a new analytical method to quantify interactions using data generated in the process of bioassay-guided fractionation is presented here: the extract fractional inhibitory concentration index (EFICI). The EFICI method uses the framework of Loewe additivity to calculate fractional inhibitory concentration values by which interactions can be determined for any combination of fractions that make up a parent extract. The EFICI method was applied to data on the bioassay-guided fractionation of Lechea mucronata and Schinus terebinthifolia for growth inhibition of the pathogenic bacterium Acinetobacter baumannii. The L. mucronata extract contained synergistic interactions (EFICI = 0.4181) and the S. terebinthifolia extract was non-interactive overall (EFICI = 0.9129). Quantifying interactions in the bioassay-guided fractionation of natural substances does not require additional experiments and can be useful to guide the experimental process and to support the development of standardized extracts as botanical drugs.Keywords
All Related Versions
Funding Information
- National Institute of Allergy and Infectious Diseases (R21 AI136563)
- Joseph W. Jones Ecological Research Center
This publication has 26 references indexed in Scilit:
- Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2Natural Product Reports, 2019
- Efficient measurement and factorization of high-order drug interactions inMycobacterium tuberculosisScience Advances, 2017
- Virulence Inhibitors from Brazilian Peppertree Block Quorum Sensing and Abate Dermonecrosis in Skin Infection ModelsScientific Reports, 2017
- When Does 2 Plus 2 Equal 5? A Review of Antimicrobial Synergy TestingJournal of Clinical Microbiology, 2014
- Revisiting the Isobole and Related Quantitative Methods for Assessing Drug SynergismThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Ellagic Acid Derivatives from Rubus ulmifolius Inhibit Staphylococcus aureus Biofilm Formation and Improve Response to AntibioticsPLOS ONE, 2012
- Acinetobacter baumannii : Emergence of a Successful PathogenClinical Microbiology Reviews, 2008
- Antimalarial drug synergism and antagonism: Mechanistic and clinical significanceFEMS Microbiology Letters, 2005
- Quantification the bioactivity of plant extracts during screening and bioassay guided fractionationPhytomedicine, 2004
- Synergy, antagonism, and what the chequerboard puts between themJournal of Antimicrobial Chemotherapy, 2003